Medicinal Chemistry Research

, Volume 28, Issue 12, pp 2270–2278 | Cite as

Identification of prodigious and under-privileged structural features for RG7834 analogs as Hepatitis B virus expression inhibitor

  • Vijay H. MasandEmail author
  • Nahed N. E. El-Sayed
  • Vesna Rastija
  • Mithilesh M. Rathore
  • Maja Karnaš
Original Research


In the present work, QSAR (quantitative structure−activity relationship) analysis has been executed for RG7834 analogs. RG7834 is a first-in-class selective and orally available dihydroquinolizinone (DHQ)-based small molecule Hepatitis B virus expression inhibitor. OECD’s guidelines have been followed for developing multiple QSAR models for Hepatitis B virus expression inhibitory activity of 73 RG7834 analogs. The present multiple QSAR models are not only easily interpretable but possess high external predictive ability, as well. These are effective in the recognition of many privileged and underprivileged molecular descriptors, which could be very valuable for the use of these models by the experts and nonexperts of QSAR in future optimizations. The models satisfy threshold values for many fitting, internal and external validation parameters, such as R2 = 0.83, Q2 = 0.80, CCCext = 0.88, etc., thereby demonstrating good external predictive ability of the models. The multiple QSAR and pharmacophoric models successfully identified a good number of important positively and negatively related structural features of RG7834 analogs that govern their Hepatitis B virus expression inhibitory activity. The results could be very beneficial to synthetic/medicinal chemists for future alterations of RG7834 analogs as better drug candidates.


RG7834 analogs Hepatitis B virus Dihydroquinolizinone QSAR Pharmacophore modeling 



Hepatitis B virus


Multiple linear regression


Quantitative structure−activity analysis


World Health Organization


Absorption, Distribution, Metabolism, Excretion and Toxicity


Ordinary least square


QSAR Insubria


Organisation for Economic Cooperation and Development


Objective feature selection


Subjective feature selection



The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding this research (Group No. RG-1435-083). Authors are grateful to Dr. Paola Gramatica and QSARINS-Chem developing team for providing QSARINS-Chem 2.2.2.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

44_2019_2455_MOESM1_ESM.docx (28 kb)
Supplementary Information
44_2019_2455_MOESM2_ESM.docx (326 kb)
Supplementary Information


  1. Aswathy L, Jisha RS, Masand VH, Gajbhiye JM, Shibi IG (2018) Design of novel amyloid β aggregation inhibitors using QSAR, pharmacophore modeling, molecular docking and ADME prediction. Silico Pharmacol 6(1):12CrossRefGoogle Scholar
  2. Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M, Dearden J, Gramatica P, Martin YC, Todeschini R, Consonni V, Kuz’min VE, Cramer R, Benigni R, Yang C, Rathman J, Terfloth L, Gasteiger J, Richard A, Tropsha A (2014) QSAR modeling: where have you been? Where are you going to? J Med Chem 57(12):4977–5010CrossRefGoogle Scholar
  3. Chtita S, Ghamali M, Ousaa A, Aouidate A, Belhassan A, Taourati AI, Masand VH, Bouachrine M, Lakhlifi T (2019) QSAR study of anti-Human African Trypanosomiasis activity for 2-phenylimidazopyridines derivatives using DFT and Lipinski’s descriptors. Heliyon 5(3):e01304CrossRefGoogle Scholar
  4. Consonni V, Ballabio D, Todeschini R (2009) Comments on the definition of the Q2 parameter for QSAR validation. J Chem Inf Model 49(7):1669–1678CrossRefGoogle Scholar
  5. Consonni V, Todeschini R, Ballabio D, Grisoni F (2019) On the misleading use of QF32 for QSAR model comparison. Mol Inform 38(1−2):e1800029CrossRefGoogle Scholar
  6. Fujita T, Winkler DA (2016) Understanding the roles of the “two QSARs”. J Chem Inf Modeling 56(2):269–274CrossRefGoogle Scholar
  7. Golbraikh A, Shen M, Xiao Z, Xiao YD, Lee KH, Tropsha A (2003) Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 17(2−4):241–253CrossRefGoogle Scholar
  8. Gramatica P (2007) Principles of QSAR models validation internal and external. QSAR Combinatorial Sci 26(5):694–701CrossRefGoogle Scholar
  9. Gramatica P, Cassani S, Roy PP, Kovarich S, Yap CW, Papa E (2012) QSAR modeling is not push a button and find a correlation: a case study of toxicity of (benzo-)triazoles on algae. Mol Inform [Online] 31:817–835CrossRefGoogle Scholar
  10. Gramatica P, Chirico N, Papa E, Cassani S, Kovarich S (2013) QSARINS: a new software for the development, analysis, and validation of QSAR MLR models. J Computational Chem 34(24):2121–2132CrossRefGoogle Scholar
  11. Gramatica P (2014) External evaluation of QSAR models, in addition to cross-validation verification of predictive capability on totally new chemicals. Mol Inform 33(4):311–314CrossRefGoogle Scholar
  12. Gramatica P, Cassani S, Chirico N (2014) QSARINS-chem: insubria datasets and new QSAR/QSPR models for environmental pollutants in QSARINS. J Computational Chem 35(13):1036–1044CrossRefGoogle Scholar
  13. Han X, Zhou C, Jiang M, Wang Y, Wang J, Cheng Z, Wang M, Liu Y, Liang C, Wang J, Wang Z, Weikert R, Lv W, Xie J, Yu X, Zhou X, Luangsay S, Shen HC, Mayweg AV, Javanbakht H, Yang S (2018) Discovery of RG7834: the first-in-class selective and orally available small molecule hepatitis B virus expression inhibitor with novel mechanism of action. J Medicinal Chem 61(23):10619–10634CrossRefGoogle Scholar
  14. Hawkins DM, Basak SC, Mills D (2003) Assessing model fit by cross-validation. J Chem Inf Comput Sci 43(2):579–586CrossRefGoogle Scholar
  15. Jisha RS, Aswathy L, Masand VH, Gajbhiye JM, Shibi IG (2017) Exploration of 3,6-dihydroimidazo(4,5-d)pyrrolo(2,3-b)pyridin-2(1H)-one derivatives as JAK inhibitors using various in silico techniques. Silico Pharmacol 5(1):9CrossRefGoogle Scholar
  16. Li X, Jie Y, You X, Shi H, Zhang M, Wu Y, Lin G, Li X, Gao Z, Chong Y (2015) Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy. Int J Clin Exp Med 8(11):21062–21070PubMedPubMedCentralGoogle Scholar
  17. Mantoani SP, de Andrade P, Chierrito TPC, Figueredo AS, Carvalho I (2019) Potential triazole-based molecules for the treatment of neglected diseases. Curr Med Chem 26(23):4403–4434CrossRefGoogle Scholar
  18. Masand VH, Mahajan DT, Ben Hadda T, Jawarkar RD, Alafeefy AM, Rastija V, Ali MA (2014a) Does tautomerism influence the outcome of QSAR modeling? Medicinal Chem Res 23:1742–1757CrossRefGoogle Scholar
  19. Masand VH, Mahajan DT, Gramatica P, Barlow J (2014b) Tautomerism and multiple modelling enhance the efficacy of QSAR: antimalarial activity of phosphoramidate and phosphorothioamidate analogues of amiprophos methyl. Medicinal Chem Res 23(11):4825–4835CrossRefGoogle Scholar
  20. Masand VH, Rastija V (2017) PyDescriptor: A new PyMOL plugin for calculating thousands of easily understandable molecular descriptors. Chemometrics Intell Lab Syst 169:12–18CrossRefGoogle Scholar
  21. Masand VH, El-Sayed NNE, Bambole MU, Quazi SA (2018) Multiple QSAR models, pharmacophore pattern and molecular docking analysis for anticancer activity of α, β-unsaturated carbonyl-based compounds, oxime and oxime ether analogues. J Mol Struct 1157:89–96CrossRefGoogle Scholar
  22. Masand VH, El-Sayed NNE, Bambole MU, Patil VR, Thakur SD (2019) Multiple quantitative structure−activity relationships (QSARs) analysis for orally active trypanocidal N-myristoyltransferase inhibitors. J Mol Struct 1175:481–487CrossRefGoogle Scholar
  23. Mueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, Ottaviani G, Lu W, Parrott NJ, Zhang JD, Schmucki R, Racek T, Hoflack J-C, Kueng E, Point F, Zhou X, Steiner G, Lütgehetmann M, Rapp G, Volz T, Dandri M, Yang S, Young JAT, Javanbakht H (2018) A novel orally available small molecule that inhibits hepatitis B virus expression. J Hepatol 68(3):412–420CrossRefGoogle Scholar
  24. Polishchuk P (2017) Interpretation of quantitative structure–activity relationship models: past, present, and future. J Chem Inf Modeling 57(11):2618–2639CrossRefGoogle Scholar
  25. Rajbhandari R, Chung RT (2016) Treatment of Hepatitis B: a concise review. Clin Transl Gastroenterol 7(9):e190CrossRefGoogle Scholar
  26. Rastija V, Molnar M, Siladi T, Masand VH (2018) QSAR analysis for antioxidant activity of dipicolinic acid derivatives. Combinatorial Chem High Throughput Screen 21(3):204–214CrossRefGoogle Scholar
  27. Roy PP, Kovarich S, Gramatica P (2011) QSAR model reproducibility and applicability: a case study of rate constants of hydroxyl radical reaction models applied to polybrominated diphenyl ethers and (benzo-)triazoles, Journal of Computational Chemistry Volume 32, Issue 11. J Computational Chem 32(11):2386–2396CrossRefGoogle Scholar
  28. Tang LSY, Covert E, Wilson E, Kottilil S (2018) Chronic hepatitis B infection. JAMA 319(17):1802–1813CrossRefGoogle Scholar
  29. Tropsha A, Gramatica P, Gombar VK (2003) The importance of being earnest validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Combinatorial Sci 22(1):69–77CrossRefGoogle Scholar
  30. Tropsha A (2012) Recent trends in statistical QSAR modeling of environmental chemical toxicity. EXS 101:381–411PubMedGoogle Scholar
  31. Yap CW (2011) PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Computational Chem 32(7):1466–1474CrossRefGoogle Scholar
  32. Yuen M-F, Chen D-S, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai C-L (2018) Hepatitis B virus infection. Nat Rev Disease Primers 4(1):18035Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Vijay H. Masand
    • 1
    Email author
  • Nahed N. E. El-Sayed
    • 2
    • 3
  • Vesna Rastija
    • 4
  • Mithilesh M. Rathore
    • 1
  • Maja Karnaš
    • 4
  1. 1.Department of ChemistryVidya Bharati MahavidyalayaAmravatiIndia
  2. 2.Department of Chemistry, College of Science, “Girls Section”King Saud UniversityRiyadhSaudi Arabia
  3. 3.National Organization for Drug Control and ResearchGizaEgypt
  4. 4.Department of Chemistry, Faculty of Agrobiotechnical SciencesJosip Juraj Strossmayer University of OsijekOsijekCroatia

Personalised recommendations